Repository logo
 

Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy

Published version
Peer-reviewed

Type

Article

Change log

Authors

Bernstock, joshua 
Peruzzotti Jametti, Luca  ORCID logo  https://orcid.org/0000-0002-9396-5607

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor and thrives in a microenvironment of relative immunosuppression. The poor clinical outcome of these malignant tumors requires the development of novel treatment options/therapeutic regimens. Accordingly, numerous immunotherapies for GBM are currently being tested in ongoing clinical trials. Herein we have examined the ability of the FDA approved drug topotecan to suppress programmed death-ligand 1 (PD-L1) expression. Our results suggest a role for topotecan as an adjuvant therapy in treatment regimens targeting certain GBM patient subpopulations in whom the expression of PD-L1 has been confirmed.

Description

Keywords

StemCellInstitute

Journal Title

Matters

Conference Name

Journal ISSN

Volume Title

Publisher

Publisher DOI

Publisher URL

Sponsorship
This research was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke/National Institutes of Health (NINDS/NIH).